Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Vistagen (NASDAQ: VTGN ) is continuing on with phase 3 development of its nasal spray containing fasedienol for social anxiety disorder. I haven't looked at VTGN since April, when I considered the name a hold, as the Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice. Analyst's Disclosure: I/we have no stock, ...